THC Global is entering the New Zealand medicinal cannabis market, saying favourable regulatory conditions will allow it to hit the ground running re-selling Endoca cannabidiol products.
And it told investors today that it has secured exclusive rights to import Endoca’s CBD products into New Zealand.
Endoca makes weed oils designed to “help balance the human endocannabinoid system”.
THC shares ticked up by a cent.
THC Global (ASX:THC) shares over the past year.
THC will import Endoca’s CBD and CBD+CBDa products from Europe through a New Zealand operating subsidiary, THC Pharma.
And it pointed to favourable regulatory conditions as a key reason for the move, saying New Zealand regulations allow prescriptions for CBD products to be made by doctors without government approval, as is required under Australian regulations.
Mr Charteris said they expect first orders “in the coming weeks” and hinted at expansion in Asia and North America.
This week South Korea became the first Asian country to legalise marijuana, beating Thailand which has been murmuring about dong so for some time.
“The company expects that this will result in rapid revenue generating sales,” Mr Charteris said.
“THC Pharma (NZ) is required to seek importation permits to commence importing Endoca products and is seeking those permits on an expedited basis.”
Get the latest Stockhead news delivered free to your inbox
For investors, getting access to the right information is critical.
Stockhead’s daily newsletters make things simple: Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.